Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Greenworks
301260
5
Tuoxin Pharmaceutical Group
301089
(Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | 10.12%1.12B | 15.41%4.54B | 17.41%3.41B | 18.54%2.21B | 16.62%1.02B | 28.97%3.93B | 26.62%2.91B | 31.64%1.87B | 17.91%875.86M | 19.70%3.05B |
Operating revenue | 10.12%1.12B | 15.41%4.54B | 17.41%3.41B | 18.54%2.21B | 16.62%1.02B | 28.97%3.93B | 26.62%2.91B | 31.64%1.87B | 17.91%875.86M | 19.70%3.05B |
Other operating revenue | ---- | -17.26%8.2M | ---- | 7.45%4.91M | ---- | 53.15%9.91M | ---- | 74.45%4.57M | ---- | 4.84%6.47M |
Total operating cost | 15.16%643.26M | 18.17%2.54B | 14.77%1.87B | 12.47%1.2B | 9.47%558.6M | 32.13%2.15B | 25.75%1.63B | 31.50%1.07B | 25.55%510.27M | 6.66%1.63B |
Operating cost | 34.61%359.76M | 19.07%1.27B | 17.64%944.28M | 13.12%605.53M | -2.57%267.26M | 17.37%1.06B | 14.85%802.67M | 21.99%535.31M | 32.41%274.31M | 23.41%906.2M |
Operating tax surcharges | 105.47%8.58M | 4.91%16M | 18.74%13.34M | 25.11%9.11M | 20.81%4.17M | 22.11%15.25M | 9.38%11.24M | 12.01%7.28M | 2.64%3.46M | 23.33%12.49M |
Operating expense | 0.30%159.88M | 13.59%714.61M | 7.99%522.48M | 2.37%334.01M | 27.23%159.4M | 37.13%629.13M | 45.30%483.83M | 55.88%326.27M | 25.29%125.29M | 24.01%458.79M |
Administration expense | -3.36%28.3M | 17.19%125.35M | -0.25%88.49M | 3.10%57.55M | 40.36%29.28M | 2,088.88%106.96M | -13.76%88.7M | -19.86%55.82M | -36.03%20.86M | -97.08%4.89M |
Financial expense | -410.32%-15.16M | -13.86%-34.75M | 10.45%-23.43M | 60.09%-12.59M | -193.86%-2.97M | 57.94%-30.52M | 63.15%-26.16M | 32.44%-31.55M | -33.88%3.16M | -349.37%-72.55M |
-Interest expense (Financial expense) | 18.95%93.53K | -2.83%421.95K | -9.63%310.44K | 14.21%194.88K | -13.93%78.63K | 58.04%434.22K | 74.43%343.54K | 50.34%170.63K | 85.20%91.35K | 79.97%274.75K |
-Interest Income (Financial expense) | -4.79%-5.55M | -20.93%-18.63M | -54.86%-13.34M | -102.52%-10.34M | -105.82%-5.3M | -183.89%-15.41M | -114.53%-8.61M | -121.94%-5.11M | -127.43%-2.57M | -46.96%-5.43M |
Research and development | 0.44%101.9M | 23.92%453.59M | 20.69%327.4M | 18.81%204.35M | 21.96%101.46M | 15.21%366.05M | 21.40%271.26M | 29.90%172M | 42.20%83.19M | 47.74%317.71M |
Credit Impairment Loss | -24.20%-10.19M | -149.72%-27.87M | -80.46%-19.63M | -39.84%-14.58M | -127.15%-8.2M | 23.88%-11.16M | 36.63%-10.88M | -13.31%-10.42M | 29.26%-3.61M | -293.55%-14.66M |
Other net revenue | -36.63%15.18M | 0.71%117.12M | -33.57%60.05M | -30.63%45.42M | -40.30%23.95M | 38.13%116.29M | 46.44%90.4M | 40.13%65.47M | 79.83%40.12M | -28.58%84.19M |
Fair value change income | -6.41%6.75M | 56.02%28.94M | -42.69%18.73M | -4.65%12.38M | -35.37%7.21M | 18.74%18.55M | 3,448.67%32.67M | 1,523.01%12.99M | 435.59%11.15M | -16.73%15.62M |
Invest income | -81.56%3.35M | 20.34%89.53M | 20.17%48.73M | 0.30%36.44M | 49.27%18.19M | 21.30%74.39M | -31.68%40.55M | -3.50%36.33M | -28.95%12.19M | 15.92%61.33M |
Asset deal income | ---- | -69.42%15.29K | 858.35%33.97K | ---- | ---- | -91.87%50K | -99.42%3.55K | ---- | ---- | 516.53%615.23K |
Other revenue | 125.88%15.27M | -23.09%26.5M | -56.54%12.19M | -57.97%11.17M | -66.86%6.76M | 61.89%34.46M | 55.81%28.04M | 43.13%26.58M | 50.09%20.4M | -44.76%21.28M |
Operating profit | 2.03%496.68M | 11.38%2.11B | 17.18%1.6B | 22.28%1.06B | 19.98%486.79M | 26.06%1.9B | 28.84%1.37B | 32.41%865.53M | 13.10%405.72M | 32.19%1.5B |
Add:Non operating Income | 13.85%22.77K | 166.73%689.21K | 90.71%430.4K | -58.67%52.18K | -80.44%20K | 107.55%258.4K | 84.23%225.68K | 14.77%126.25K | 34.53%102.25K | 83.09%124.5K |
Less:Non operating expense | 161.77%854.08K | 615.16%18.67M | 1,060.38%18.23M | 1,214.30%18.14M | 2.00%326.27K | 2.74%2.61M | 29.45%1.57M | 59.21%1.38M | -50.91%319.86K | 29.27%2.54M |
Total profit | 1.93%495.85M | 10.57%2.09B | 15.99%1.58B | 20.37%1.04B | 19.97%486.48M | 26.10%1.89B | 28.85%1.37B | 32.37%864.28M | 13.22%405.5M | 32.20%1.5B |
Less:Income tax cost | -3.19%58.34M | 10.58%264.74M | 12.00%200.39M | 20.01%137.15M | 19.49%60.26M | 38.16%239.41M | 32.23%178.91M | 37.14%114.28M | 1.56%50.43M | 7.08%173.28M |
Net profit | 2.65%437.51M | 10.57%1.83B | 16.59%1.38B | 20.42%903.15M | 20.04%426.22M | 24.53%1.65B | 28.35%1.19B | 31.68%750M | 15.10%355.07M | 36.38%1.33B |
Net profit from continuing operation | 2.65%437.51M | 10.57%1.83B | 16.59%1.38B | 20.42%903.15M | 20.04%426.22M | 24.53%1.65B | 28.35%1.19B | 31.68%750M | 15.10%355.07M | 36.38%1.33B |
Net profit of parent company owners | 2.65%437.51M | 10.57%1.83B | 16.59%1.38B | 20.42%903.15M | 20.04%426.22M | 24.53%1.65B | 28.35%1.19B | 31.68%750M | 15.10%355.07M | 36.38%1.33B |
Earning per share | ||||||||||
Basic earning per share | 2.64%0.5568 | 10.53%2.3271 | 16.55%1.7609 | 20.40%1.1495 | 19.97%0.5425 | 24.53%2.1054 | 28.43%1.5108 | 31.76%0.9547 | 15.18%0.4522 | 36.13%1.6907 |
Diluted earning per share | 2.64%0.5568 | 10.59%2.3271 | 16.62%1.7609 | 20.47%1.1495 | 20.10%0.5425 | 24.61%2.1043 | 28.47%1.51 | 31.83%0.9542 | 15.20%0.4517 | 36.32%1.6887 |
Other composite income | -67.75%-10.25M | -128.37%-10.98M | -137.47%-23.08M | -133.04%-16.44M | -16,006.33%-6.11M | 213.43%38.71M | 364.37%61.6M | 22,443.86%49.75M | 114.49%38.43K | 529.18%12.35M |
Other composite income of parent company owners | -67.75%-10.25M | -128.37%-10.98M | -137.47%-23.08M | -133.04%-16.44M | -16,006.33%-6.11M | 213.43%38.71M | 364.37%61.6M | 22,443.86%49.75M | 114.49%38.43K | 529.18%12.35M |
Total composite income | 1.70%427.26M | 7.39%1.82B | 8.99%1.36B | 10.87%886.71M | 18.31%420.11M | 26.27%1.69B | 33.10%1.25B | 40.47%799.75M | 15.21%355.11M | 37.37%1.34B |
Total composite income of parent company owners | 1.70%427.26M | 7.39%1.82B | 8.99%1.36B | 10.87%886.71M | 18.31%420.11M | 26.27%1.69B | 33.10%1.25B | 40.47%799.75M | 15.21%355.11M | 37.37%1.34B |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
Auditor | -- | Zheng Dan Zhiyuan (Shenzhen) Certified Public Accountants (Special General Partnership) | -- | -- | -- | Shenzhen Dahua International Accounting Firm (Special General Partnership) | -- | -- | -- | Dahua Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.